BC Partners agrees to sell majority stake in Synthon to Goldman Sachs Alternatives

Synthon is a Netherlands-headquartered pharmaceutical company.

16 December 2024•2 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.